TY - JOUR T1 - SARS-CoV-2 Reinfection is Preceded by Unique Biomarkers and Related to Initial Infection Timing and Severity: an N3C RECOVER EHR-Based Cohort Study JF - medRxiv DO - 10.1101/2023.01.03.22284042 SP - 2023.01.03.22284042 AU - Emily Hadley AU - Yun Jae Yoo AU - Saaya Patel AU - Andrea Zhou AU - Bryan Laraway AU - Rachel Wong AU - Alexander Preiss AU - Rob Chew AU - Hannah Davis AU - Christopher G Chute AU - Emily R Pfaff AU - Johanna Loomba AU - Melissa Haendel AU - Elaine Hill AU - Richard Moffitt AU - the N3C and RECOVER consortia AU - the N3C and RECOVER consortia Y1 - 2023/01/01 UR - http://medrxiv.org/content/early/2023/01/05/2023.01.03.22284042.abstract N2 - Although the COVID-19 pandemic has persisted for over 2 years, reinfections with SARS-CoV-2 are not well understood. We use the electronic health record (EHR)-based study cohort from the National COVID Cohort Collaborative (N3C) as part of the NIH Researching COVID to Enhance Recovery (RECOVER) Initiative to characterize reinfection, understand development of Long COVID after reinfection, and compare severity of reinfection with initial infection. We validate previous findings of reinfection incidence (5.9%), the occurrence of most reinfections during the Omicron epoch, and evidence of multiple reinfections. We present novel findings that Long COVID diagnoses occur closer to the index date for infection or reinfection in the Omicron BA epoch. We report lower albumin levels leading up to reinfection and a statistically significant association of severity between first infection and reinfection (chi-squared value: 9446.2, p-value: 0) with a medium effect size (Cramer’s V: 0.18, DoF = 4).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Institutes of Health Agreement OTA OT2HL161847 as part of the Researching COVID to Enhance Recovery (RECOVER) research program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRBs of RTI International, Stony Brook University, the University of Colorado, the University of North Carolina, and the University of Virginia gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study is available through the N3C Enclave to approved users. See https://covid.cd2h.org/for-researchers for instructions on how to access the data. https://covid.cd2h.org/for-researchers ER -